Lonza reports softer performance in Q1 2024

Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s

Jubilant Pharmova to close manufacturing operations of Solid dosage formulation facility of Jubilant Cadista USA

The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.

Lupin launches first generic version of Oracea in US

Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients

Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly

Caplin Group commences operations of Rs. 150 crore oncology facility

The facility will manufacture tablets, capsules, and injections for the oncology segment

USFDA grants orphan drug and pediatric exclusivities for Cresemba for aspergillosis and mucormycosis in children

CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications

Sakar's oncology unit receives EU GMP approval

The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters

Strides receives USFDA approval for Gabapentin Tablets

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty

Strides Pharma Science to invest in AMP-6, AMP-8

AMP-6 & AMP-8 are special purpose entities formed for purpose of setting up captive solar power projects in Karnataka

Natco Pharma and Breckenridge dismissed from antitrust lawsuit